Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

BNTCAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.76+ 1.34%S&P 500 · SPY770.20+ 0.63%Dow Jones · DIA523.16+ 0.04%Russell 2000 · IWM280.24+ 1.17%

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
Benzinga04:374 Days AgoBNTC+1.0%

03:00Oct 231 Story

Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
Benzinga03:10BNTC+1.0%

08:00Oct 51 Story

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
The BB-301 pivotal trial remains on track to begin in mid-2027Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History StudyFinal pivotal study design expected to be confirmed in 1Q 2027Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encom
Yahoo08:00BNTC+1.0%

08:00Sep 251 Story

After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Yahoo08:35BNTC+1.0%

05:00Sep 151 Story

Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
Benzinga05:38BNTC+1.0%

12:00-17:00Sep 142 Stories

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberAdditional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking
Yahoo16:00BNTC+1.0%
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
Benzinga12:09BNTC

▲+1.0%